MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Market Closed 01-23 16:00:00 EST

12.50

+0.14

+1.13%

盘后12.50

+0.000.00%

16:10 EST

High12.52	Low11.56	Vol14.02K
Open12.12	D1 Closing12.36	Amplitude7.78%
Mkt Cap58.68M	Tradable Cap21.29M	Total Shares4.69M
T/O172.76K	T/O Rate0.82%	Tradable Shares1.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":12.5,"timestamp":1769202000000,"preClose":12.36,"halted":0,"volume":14022,"hourTrading":{"tag":"盘后","latestPrice":12.5,"preClose":12.5,"latestTime":"16:10 EST","volume":6,"amount":74.94,"timestamp":1769202604987,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.011326860841423994,"floatShares":1703200,"shares":4694155,"eps":-3.021903,"marketStatus":"Market Closed","change":0.14,"latestTime":"01-23 16:00:00 EST","open":12.12,"high":12.524,"low":11.5625,"amount":172755.28559,"amplitude":0.077791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.021903,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":12.36,"preHourTrading":{"tag":"盘前","latestPrice":12.01,"preClose":12.36,"latestTime":"09:12 EST","volume":4,"amount":48.04,"timestamp":1769177571463,"change":-0.35,"changeRate":-0.028317,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.5,"preClose":12.5,"latestTime":"16:10 EST","volume":6,"amount":74.94,"timestamp":1769202604987,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4547453919181195},"requestUrl":"/m/hq/s/INKT/tweets","defaultTab":"tweets","newsList":[{"id":"2602515391","title":"MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602515391?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:10","pubTimestamp":1767892224,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced the upcoming initiation of a Phase 1, investigator-sponsored clinical trial evaluating its lead therapy, agenT-7...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-university-of-wisconsin-madison-announce-phase-1-agent-797-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-university-of-wisconsin-madison-announce-phase-1-agent-797-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2602039945","title":"MiNK Therapeutics Wins Grants to Advance Phase 1 Trial of Allo-iNKT Cell Therapy for GvHD Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2602039945","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602039945?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:00","pubTimestamp":1767891615,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics Inc. has announced the initiation of a Phase 1 clinical trial of its lead therapy, agenT-797, for the prevention of graft-versus-host disease  in patients undergoing allogeneic hematopoietic stem cell transplantation. The trial is supported by two complementary public-private funding awards: an NIH STTR grant from the National Institute of Allergy and Infectious Diseases  and the Mary Gooze Clinical Trial and Translation Award to the University of Wisconsin-Madison. Both MiNK Therapeutics and the University of Wisconsin-Madison are beneficiaries of these grants, enabling the advancement of preclinical and clinical studies of allo-iNKT cell therapy in transplantation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL6t0MLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014021.USD","INKT","BK4585","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2602994323","title":"Mink Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-Inkt Cell Therapy (Agent-797) to Evaluate Prevention of Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2602994323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602994323?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:00","pubTimestamp":1767891600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA53FS1T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2600609875","title":"MiNK Therapeutics Director Robert Kadlec Resigns for U.S. Government Role","url":"https://stock-news.laohu8.com/highlight/detail?id=2600609875","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600609875?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:06","pubTimestamp":1767387962,"startTime":"0","endTime":"0","summary":"Robert Kadlec, MD, has resigned from the Board of Directors of MiNK Therapeutics, Inc., effective December 29, 2025. His departure follows his acceptance of a senior public service role within the United States government.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL7ZQP5x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2585156148","title":"MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2585156148","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585156148?lang=en_us&edition=fundamental","pubTime":"2025-11-21 00:42","pubTimestamp":1763656967,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics Inc. has announced new preclinical research results for its novel therapy, MiNK-215, which targets solid tumors resistant to current immunotherapies. The findings, now published in Cancer Immunology Research, show that MiNK-215-an IL-15-enhanced, FAP-targeting CAR-iNKT cell therapy-can effectively dismantle tumor-protective fibroblast barriers, remodel the tumor microenvironment, and activate multiple immune pathways. In models of lung and microsatellite stable  colorectal cancer, MiNK-215 promoted immune cell infiltration, activated dendritic cells, re-polarized macrophages, and enabled robust anti-tumor activity. As an off-the-shelf, allogeneic therapy, MiNK-215 offers a scalable treatment option for patients with solid tumors that have not responded to conventional immune-based therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL2JCzVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","INKT","BK4585","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2583833956","title":"MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2583833956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583833956?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:55","pubTimestamp":1763139339,"startTime":"0","endTime":"0","summary":"In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics, with a price target of $35.00. Emily Bo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mink-therapeutics-advancing-clinical-trials-and-strategic-partnerships-to-address-gvhd-and-pulmonary-diseases-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mink-therapeutics-advancing-clinical-trials-and-strategic-partnerships-to-address-gvhd-and-pulmonary-diseases-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2583948509","title":"MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583948509","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583948509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:23","pubTimestamp":1763126597,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 5.69 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48862390/mink-therapeutics-q3-eps-0-65-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"gpt_icon":0},{"id":"2583459505","title":"MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583459505","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583459505?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:35","pubTimestamp":1763123756,"startTime":"0","endTime":"0","summary":"“This trial reflects the broader momentum of our iNKT platform as we expand into diseases marked by profound immune dysregulation,” said Dr. Terese...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-q3-eps-65c-vs-46c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-q3-eps-65c-vs-46c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT"],"gpt_icon":0},{"id":"2583686505","title":"Mink Therapeutics Q3 EPS USD -0.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583686505?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:32","pubTimestamp":1763123532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX398BF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2583505685","title":"Mink Therapeutics Inc: Cash Runway Extended Through 2026, Enabling Multiple Inflection Points","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505685?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:30","pubTimestamp":1763123400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA6TXZWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2583505535","title":"Mink Therapeutics Reports Q3 2025 Results and Accelerates Inkt Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505535?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:30","pubTimestamp":1763123400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA6TXZWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2583505358","title":"Press Release: MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505358?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:30","pubTimestamp":1763123400,"startTime":"0","endTime":"0","summary":"-- New clinical data show durable remissions and long-tail survivors. -- GVHD trial launching through non-dilutive funding from NIH- and. -- Launching Phase 2+ trial in severe pulmonary disease in US population. -- Added national leaders in pulmonary medicine, trauma, and biodefense join. -- Cash runway extended through 2026, enabling multiple inflection points. -- Durable clinical responses in refractory solid tumors with agenT-797At. SITC 2025, MiNK reported updated clinical data showing sustained tumor. regression and immune reprogramming with its lead asset agenT-797 across. than two years and survival exceeding two and three years in late stage,Center--Madison, MiNK initiated a preclinical and Phase 1 study of. Jenny Gumperz, is supported by the Mary Gooze Clinical Trial and. \"This trial reflects the broader momentum of our iNKT platform as we expand into diseases marked by profound immune dysregulation,\" said Dr. Terese Hammond, Head of Inflammatory and Pulmonary","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2581383400","title":"BRIEF-Mink Therapeutics Inc - Files For Mixed Shelf Offering Up To $150 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581383400","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581383400?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:11","pubTimestamp":1762553487,"startTime":"0","endTime":"0","summary":"BRIEF-Mink Therapeutics Inc - Files For Mixed Shelf Offering Up To $150 Million - SEC FilingMink Therapeutics Inc INKT.O:MINK THERAPEUTICS INC - FILES FOR MIXED SHELF OFFERING UP TO $150 MILLION - SEC FILINGSource text: [ID:n0001193125-25-272532]Further company coverage: INKT.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2581783263","title":"MiNK Therapeutics files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2581783263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581783263?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:00","pubTimestamp":1762552818,"startTime":"0","endTime":"0","summary":"16:58 EST MiNK Therapeutics (INKT) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"gpt_icon":0},{"id":"2581883890","title":"Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581883890","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581883890?lang=en_us&edition=fundamental","pubTime":"2025-11-08 01:35","pubTimestamp":1762536937,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics, retaining the price target of $35.00. Emily Bodnar’s rating i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-phase-1-results-for-mink-therapeutics-agent-797-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-phase-1-results-for-mink-therapeutics-agent-797-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT"],"gpt_icon":0},{"id":"2581882715","title":"BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882715?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:01","pubTimestamp":1762531314,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton InteractiveEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL6N3WJ0UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LDOS","TASK","CNH","OGN","IE00B19Z9Z06.USD","KKR","ABNB","NEM","DKNG","MNST","FLR","OLED","INKT","HL","FROG","CMI","MCHP","SOLV","ANIP","GIFI","VOYG","AIRS","CDE","BK4187","INOD","HAE","AFRM","CEG","WEN","GMED","TTD","RRR","AKAM","FLGT","TXG","RYTM","PTON","NTLA","XYZ","TSYW.SI","GRND","CE"],"gpt_icon":1},{"id":"2581288952","title":"BUZZ-MiNK Therapeutics rises after data shows long-lasting remissions in tough cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2581288952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581288952?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:24","pubTimestamp":1762525443,"startTime":"0","endTime":"0","summary":"BUZZ-MiNK Therapeutics rises after data shows long-lasting remissions in tough cancers** Shares of drug developer MiNK Therapeutics INKT.O rise 2% to $13.93 premarket ** Co says its experimental cell therapy, agenT-797, shows lasting benefits for patients with advanced cancers who had stopped responding to other treatments** INKT says patients who received agenT-797, either alone or with an existing immunotherapy drug, lived for a median of about 23 months** Some patients with tough-to-treat cancers, including testicular, thymoma, and gastric cancers, saw their disease controlled for more than two years - co** Doctors say that one patient with metastatic testicular cancer experienced a complete remission lasting over two years after receiving the combination therapy - INKT** Other patients with different cancers also saw their tumors shrink or stop growing for extended periods, co says** Up to last close, stock up 96% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL4N3WJ19E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2581898388","title":"MiNK Therapeutics reports updated clinical results on agenT-797","url":"https://stock-news.laohu8.com/highlight/detail?id=2581898388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581898388?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524354,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-updated-clinical-results-on-agent-797-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-updated-clinical-results-on-agent-797-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4139"],"gpt_icon":0},{"id":"2581886589","title":"MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886589","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886589?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524048,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T  cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer  Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5Zs459:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2095319765.USD","INKT","BK4139","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581888681","title":"Mink Therapeutics Reports Durable Responses and Immune Reactivation With Allo-Inkt Cell Therapy Agent-797 in Pd-1–Refractory Solid Tumors at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888681?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA3DN3DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0504},{"period":"3month","weight":-0.1653},{"period":"6month","weight":-0.3265},{"period":"1year","weight":0.2819},{"period":"ytd","weight":0.1211}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.02848},{"month":2,"riseRate":0.25,"avgChangeRate":-0.041821},{"month":3,"riseRate":0,"avgChangeRate":-0.089419},{"month":4,"riseRate":0.25,"avgChangeRate":-0.026851},{"month":5,"riseRate":0,"avgChangeRate":-0.100407},{"month":6,"riseRate":0.5,"avgChangeRate":0.033071},{"month":7,"riseRate":0.25,"avgChangeRate":0.215487},{"month":8,"riseRate":0.25,"avgChangeRate":0.146012},{"month":9,"riseRate":0,"avgChangeRate":-0.132506},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}